Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance

Leukemia

Volumn 28, Issue 8, 2014, Pages 1698-1704

  Xu, L ^a,b   Hunter, Z R ^a,b   Yang, G ^a,b   Cao, Y ^a,b   Liu, X ^a,b   Manning, R ^a   Tripsas, C ^a   Chen, J ^a   Patterson, C J ^a   Kluk, M ^b,c   Kanan, S ^a   Castillo, J ^a,b   Lindeman, N ^b,c   Treon, S P ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS, CD19; HEMOGLOBINS; HUMANS; IMMUNOGLOBULIN M; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; WALDENSTROM MACROGLOBULINEMIA;

EID: 84905690468     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.65     Document Type: Article

References (32)

1. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 110-115.
2. Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn. IARC Press: Lyon, France, 2008.
3. Treon SP. How I treat Waldenström macroglobulinemia. Blood 2009; 17 114: 2375-2385.
4. Smith BR, Robert NJ, Ault KA. In Waldenstrom's macroglobulinemia the quantity of detectable circulating monoclonal B lymphocytes correlates with clinical course. Blood 1983; 61: 911-914.
5. Kriangkum J, Taylor BJ, Treon SP, Mant MJ, Belch AR, Pilarski LM. Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood 2004; 104: 2134-2142.
6. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 3470: 115-119.
7. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 2012; 367: 826-833.
8. Treon SP, Hunter ZR. MYD88 L265P Somatic Mutation in IgM MGUS. N Engl J Med 2012; 367: 2256-2257.
9. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allelespecific polymerase chain reaction. Blood 2013; 121: 2051-2058.
10. Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med 2012; 367: 2255-2256.
11. Gachard N, Parrens M, Soubeyran I, Petit B, Marfak A, Rizzo D et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia 2013; 27: 183-189.
12. Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Pascutto C et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood 2013; 121: 2522-2528.
13. Jimenez C, Sebastian E, Del Carmen Chillon M, Giraldo P, Mariano Hernández J, Escalante F et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia. Leukemia 2013; 27: 1722-1728.
14. Poulain S, Roumier C, Decambron A, Renneville A, Herbaux C, Bertrand E et al. MYD88 L265P mutation in Waldenstrom's macroglobulinemia. Blood 2013; 121: 4504-4511.
15. Willenbacher W, Willenbacher E, Brunner A, Manzi C. Improved accuracy of discrimination between IgM multiple myeloma and Waldenstrom macroglobulinaemia by testing for MYD88 L265P mutations. Br J Haematol 2013; 161: 902-904.
16. Ondrejka SL, Lin JJ, Warden DW, Durkin L, Cook JR, Hsi ED. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders. Am J Clin Pathol 2013; 140: 387-394.
17. Argentou N, Vassilopoulos G, Ioannou M, Germenis AE, Speletas M. Rapid detection of MYD88-L265P mutation by PCR-RFLP in B-cell lymphoproliferative disorders. Leukemia 2014; 28: 447-449.
18. Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-105.
19. Watters T, Kenny EF, O'Neill LAJ. Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol Cell Biol 2007; 85: 411-419.
20. Loiarro M, Gallo G, Fantò N, De Santis R, Carminati P, Ruggiero V et al. Identification of critical residues of the MYD88 death domain involved in the recruitment of downstream kinases. J Biol Chem 2009; 284: 28093-281023.
21. Lin SC, Lo YC, Wu H. Helical assembly in the MYD88-IRAK4-IRAK2 complex in TLR/IL-1R signaling. Nature 2010; 465: 885-891.
22. Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood 2013; 122: 1222-1232.
23. Treon SP, Tripsas C, Yang G, Cao Y, Xu L, Hunter ZR et al. 2013A Prospective Multicenter Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia. Blood 2013; 122: Abstract 251.
24. Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 116-120.
25. Kiss TL, Xu WM, Jamal N, Messner HA. Comparative testing of peripheral blood and bone marrow for BCR-ABL transcripts in patients post allogeneic bone marrow transplantation and during interferon treatment for chronic myeloid leukemia. Leuk Lymphoma 1999; 34: 493-500.
26. Passamonti F. How I treat polycythemia vera. Blood 2012; 120: 275-284.
27. Tiacci E, Schiavoni G, Forconi F, Santi A, Trentin L, Ambrosetti A et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood 2012; 119: 192-195.
28. Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J et al. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood 2008; 112: 150-158.
29. Hodge LS, Ziesmer SC, Yang ZZ, Secreto FJ, Gertz MA, Novak AJ et al. IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia. Blood 2012; 120: 3774-3782.
30. Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007; 13: 3320-3325.
31. Treon SP, Tripsas CK, Meid K, Patterson CJ, Heffner LT, Eradat H et al. Prospective, multicenter study of the MTOR inhibitor everolimus (RAD001) as primary therapy in Waldenstrom's macroglobulinemia. Blood 2013; 122: Abstract 1822.
32. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S et al. Multiple Myeloma, version 1.2013. J Natl Compr Canc Netw 2013; 11: 11-17.